Certain phorbol esters, polar solvents and retinoids have been identified as in vitro and in vivo inducers of human myeloid leukemia cell differentiation. These findings have indicated that factor-independent growth of myeloid leukemia cells is reversible. The mechanisms by which these agents induce terminal differentiation, however, are unknown. Our work has focused on induction of the stress activated protein kinase (SAPK/JNK) as a signal that directs cellular differentiation. The results indicate that SAPK activates the c-jun and EGR-1 early response genes and thereby in part the differentiated phenotype. SAPK also targets the release of mitochondrial cytochrome c to integrate apoptosis with terminal differentiation. Our studies have shown that activation of protein kinase C-beta (PKC-beta) in the response to phorbol esters is essential for induction of SAPK and differentiation. PKC-beta-mediated signals induce the production of reactive oxygen species (ROS) and thereby the activation of SAPK. The findings also demonstrate that PKC-beta and the related PKC-beta isoform are each targeted to the nucleus and mitochondria in the phorbol ester response of myeloid leukemia cells. The proposed work will extend these studies by defining the effectors downstream to PKC-beta and PKC-beta that regulate the differentiation program. Our hypothesis is that PKC-beta- and PKC-beta-activated pathways function in concert to integrate nuclear and mitochondrial signals that confer terminal differentiation.
The Specific Aims are: 1) To further define PKC-beta- and ROS-dependent activation of SAPK in TPA-induced nuclear and mitochrondial signaling; 2) To study the functional significance of targeting PKC-beta to the nucleus and mitochrondial in the induction of myeloid leukemia cell differentiation; 3) To define the role of PKC-beta in nuclear and mitochondrial signaling associated with terminal differentiation; and 4) To study integration of the differentiated phenotype with apoptosis in the induction of terminal differentiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042802-17
Application #
6606167
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Howcroft, Thomas K
Project Start
1986-08-01
Project End
2007-01-31
Budget Start
2003-02-01
Budget End
2004-01-31
Support Year
17
Fiscal Year
2003
Total Cost
$324,900
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Jain, Salvia; Stroopinsky, Dina; Yin, Li et al. (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354-62
Raina, Deepak; Agarwal, Praveen; Lee, James et al. (2015) Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One 10:e0135156
Yin, Li; Kufe, Turner; Avigan, David et al. (2014) Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood 123:2997-3006
Liu, Suiyang; Yin, Li; Stroopinsky, Dina et al. (2014) MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123:734-42
Liu, Yan; Marks, Kevin; Cowley, Glenn S et al. (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3:870-9
Stroopinsky, Dina; Rosenblatt, Jacalyn; Ito, Keisuke et al. (2013) MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res 73:5569-79
Jin, C; Rajabi, H; Rodrigo, C M et al. (2013) Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 32:2179-88
Hong, David S; Kurzrock, Razelle; Supko, Jeffrey G et al. (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18:3396-406
Yin, Li; Kosugi, Michio; Kufe, Donald (2012) Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood 119:810-6
Jin, Caining; Rajabi, Hasan; Pitroda, Sean et al. (2012) Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One 7:e39432

Showing the most recent 10 out of 130 publications